Biotech

All Articles

Vaxcyte climbs on 'magnificent' 31-valent PCV succeed against Pfizer

.Vaxcyte unveiled what experts called "spectacular" period 1/2 records for its 31-valent pneumococca...

Recursion's brain condition test presents little evidence of effectiveness

.Recursion has actually discovered via an early test of its own tech-enabled technique to medication...

Acepodia, Pfizer click on with each other for chemistry-based cell therapy

.Contact it an instance of good chemistry: Acepodia, a biotech based on Nobel Champion scientific re...

Praxis epilepsy medication decreases seizures in phase 2 hearing

.Practice Preciseness Medicines has racked up one more midphase gain in epilepsy this year, along wi...

Three directors surrender as Dyne blog posts combined records for DMD candidate

.After getting away a clinical hold many years back, Dyne Therapeutics has actually exposed brand ne...

Arrowhead fires off phase 3 information in uncommon metabolic disease in front of market clash with Ionis

.Arrowhead Pharmaceuticals has actually shown its own hand in advance of a prospective face-off alon...

Pfizer, Valneva reveal lyme ailment try successful for 2nd booster

.Pfizer and Valneva might have concerning 2 even more years to hang around prior to they make the in...

Fierce Biotech Managing Editor Ayla Ellison Talks Shop with Michelle Benz on the Future of Biotech.

.Let's study a conversation along with Ayla Ellison, Fierce Biotech Editor-in-Chief and also Michell...

New data show how Bayer's asundexian fell short to stop strokes

.Bayer put on hold the phase 3 trial for its aspect XIa inhibitor asundexian late in 2015 after the ...

Sanofi's tolebrutinib fails 2 of 3 late-stage MS tests

.Sanofi is actually still bented on taking its multiple sclerosis (MS) med tolebrutinib to the FDA, ...